New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
sheila RHEUMarampa
2 months ago
This study evaluated the risk of flares after sustained drug-free rem in SLE.
% of pts w/ reported flares w/n yrs in rem:
48.6% at 2yrs
42.3% at 3yrs
35.2% at 5 yrs
Mucocut, msk, renal & immuno - ⬆️affected domain
Reassess pts regularly.
POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh
Jiha Lee JihaRheum
2 months ago
@RheumNow article further exploring the roe of lung ultrasound for RA-ILD screening as shown through 3 #EULAR2026 abstracts
https://t.co/smN8hg51nj
Nelly ZIADE 🍀 Nellziade
2 months ago
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow https://t.co/IhGQSxssyd
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and classification criteria for the Anti-Synthetase Syndrome. Here are but a few of my favorites from a list of many quality sessions.
Janet Pope Janetbirdope
2 months ago
Some new #vaccination #recommendations
#EULAR2026
@RheumNow https://t.co/j7cOJPpOcV https://t.co/VnGkFwTZ86
Janet Pope Janetbirdope
2 months ago
Remember
Babies of pts on chronic #immunosuppression with #SARDs
❎delay #vaccinations til 6/12
For safety & to mount sufficient response
#rotovirus #vaccine is Ok before 6 months or vaccine is ineffective
Pts w #SARDs need #COVID shots
@RheumNow #EULAR2026 #vaccine #recom https://t.co/WEzNajWlxY
sheila RHEUMarampa
2 months ago
What’s new with the 2026 update of reco for vax in AIIRD?
Vaccinate as soon as possible
Non-live vaccines are safe
Hold MTX for upto 2wks to inc vax yield
Strong reco for RZV
Catch-up vax for HPV in SLE
Rotavirus vax for newborns exposed in utero to TNFi
@RheumNow #EULAR2026 https://t.co/RZbyvAcYRI
Janet Pope Janetbirdope
2 months ago
#EULAR2026 #SARD #vaccination #recommendations
I think 🤔
✅proactive➡️take responsibility
✅close gap
✅mostly practical
But
How long will #shingrix work if #vaccine
In age<50yrs
When if ever
To revaccinate?
@RheumNow @eular_org @ACRheum https://t.co/najJwzdecL
Mrinalini Dey DrMiniDey
2 months ago
#OP0156 #EULAR2026 FT839, CART therapy targeting CD19 & CD38, showed potent depletion of pathogenic B cells, plasmablasts/plasma cells & activated T cells, w/o conditioning chemotherapy. Data suggest potentially more accessible CART approach across autoimmune diseases. @RheumNow https://t.co/9COyXbghkl
Jiha Lee JihaRheum
2 months ago
Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in head-to-head. But evidence on non-pharmacologic strategies in D2T RA remains nearly absent. Clear gap for future trials. @RheumNow #EULAR2026 POS1246
Janet Pope Janetbirdope
2 months ago
Good performance of #definite
#antisynthetase #syndrome
✅+antibody mandatory
Possible also does ok
@RheumNow #EULAR2026
June 6 #antisynthetase #classifiaction #criteria https://t.co/5sxogTX9YT
